- Puma Biotechnology Inc stock price today and history
Puma Biotechnology Inc (PBYI) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Puma Biotechnology Inc stock price
Puma Biotechnology Inc latest news:
Puma Biotech shares drop more than 20% as European OK of breast cancer drug unlikely
Puma Biotechnology Inc. shares fell Tuesday after the biotech company said it will likely not get a positive result on its European marketing application for a breast cancer treatment. Puma Biotechnology shares dropped 25% to $68 after hours. The company said the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a "negative trend vote" for the drug neratinib to treat early stage HER2-positive breast cancer, meaning it will not likely get approval in a decision scheduled in February, and that additional steps would likely be needed to get a positive approval. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, ...
Puma Biotechnology Inc(PBYI): * PUMA BIOTECHNOLOGY ANNOUNCES RESULTS OF CHMP ORAL EXPLANATION FOR NERATINIB FOR EXTENDED ADJUVANT TREATMENT OF HER2-POSITIVE EARLY STAGE BREAST CANCER.
BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, Neratinib
* PUMA BIOTECHNOLOGY ANNOUNCES RESULTS OF CHMP ORAL
FOR NERATINIB FOR EXTENDED ADJUVANT TREATMENT OF HER2-POSITIVE
EARLY STAGE BREAST CANCER
BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application
* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR
PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY
BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer
* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH
COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER
Source text for Eikon:
Further company coverage:
BRIEF-Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings
Puma Biotechnology Inc(PBYI): * PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS. * PUMA BIOTECHNOLOGY(PBYI) - EUROPEAN PATENT OFFICE HAS UPHELD CLAIMS IN PUMA'S LICENSED EUROPEAN PATENT, EP 2416774, WHICH WERE BEING OPPOSED BY HEXAL AG Source text for Eikon: Further company coverage:
Putnam High Income Bond FundPCF
Putnam Managed Municipal Income TrustPMM
Putnam Master Intermediate Income TrustPIM
Putnam Municipal Opportunities TrustPMO
Putnam Premier Income TrustPPT
Pzena Investment Management IncPZN
Qihoo 360 Technology Co. Ltd.QIHU